Eli Lilly CEO David Ricks (L) and Sanofi CEO Paul Hudson at a Senate hearing entitled 'The Need to Make Insulin Affordable for All Americans' (Al Drago/Bloomberg via Getty Images)

August 31, 2023 04:11 PM EDTUpdated September 1, 10:59 AM

FDA+

Lilly, Novo, Sanofi face pressure from lawmakers to clarify low-cost insulin programs

Lia DeGroot

Sens. Maggie Hassan (D-NH) and Tina Smith (D-MN) are asking the three major insulin manufacturers — Eli Lilly, Novo Nordisk, and Sanofi — to provide more details …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Lilly, Novo, Sanofi face pressure from lawmakers to clarify low-cost insulin programs

Lia DeGroot

Sign up to read this article for free.

Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Roche’s Parkinson’s drug flunks second mid-stage trial

David Epstein gets $140M for Ottimo's bifunctional take on hot PD-1xVEGF field

Sangamo strikes another brain-targeting AAV partnership, this time with Astellas

Bristol Myers pays $100M upfront to collaborate with Leqembi originator in Alzheimer's

Lil­ly, No­vo, Sanofi face pres­sure from law­mak­ers to clar­i­fy low-cost in­sulin pro­grams

Lia DeGroot

Sign up to read this article for free.

more like this

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Roche’s Parkin­son’s drug flunks sec­ond mid-stage tri­al

David Ep­stein gets $140M for Ot­ti­mo's bi­func­tion­al take on hot PD-1xVEGF field

Sang­amo strikes an­oth­er brain-tar­get­ing AAV part­ner­ship, this time with Astel­las

Bris­tol My­ers pays $100M up­front to col­lab­o­rate with Leqem­bi orig­i­na­tor in Alzheimer's

Lilly, Novo, Sanofi face pressure from lawmakers to clarify low-cost insulin programs

Updated: Vertex’s non-opioid pill disappoints in mid-stage chronic pain study

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

Roche’s Parkinson’s drug flunks second mid-stage trial

David Epstein gets $140M for Ottimo's bifunctional take on hot PD-1xVEGF field

Sangamo strikes another brain-targeting AAV partnership, this time with Astellas

Bristol Myers pays $100M upfront to collaborate with Leqembi originator in Alzheimer's